



ASX Announcement

For immediate release

17 December 2015

Bluechiip announces Capital Raising

Placement

Bluechiip Limited ("**Bluechiip**" or the "**Company**") (ASX: BCT) is pleased to announce that it has successfully completed a placement to sophisticated and professional investors raising \$450,000.

Henslow acted as lead manager for the placement.

The placement comprises 11,250,000 ordinary fully paid shares at an issue price of \$0.04 per ordinary share. The net funds raised will be used to fund ongoing working capital requirements.

Settlement of the placement will occur on 18 December 2015 with allotment of the placement shares to occur on 22 December 2015.

Share Purchase Plan

In addition to the placement, a share purchase plan will be offered to eligible shareholders in Australia and New Zealand ("**SPP**"). Under the SPP, holders of existing Bluechiip shares on the share register as at 7.00pm (Sydney time) on the record date of Wednesday, 16 December 2015 and who are eligible shareholders in Australia or New Zealand will each be invited to subscribe for up to A\$15,000 of new fully paid ordinary shares in Bluechiip.

Participation in the SPP is optional and the SPP will not be underwritten. Further information in relation to the SPP, including the SPP terms and conditions, will be outlined in a separate SPP Booklet which will be despatched to eligible shareholders.

Andrew McLellan, Bluechiip Managing Director & CEO, said *"We are pleased to have secured the placement funds and offer all our existing shareholders the opportunity to invest via the Share Purchase Plan. The fresh funds will enable Bluechiip to continue to execute on our strategy and deliver on our valuable partnerships, including the recently announced agreement with Genea Biomedx in the IVF market. Our new product offerings have been well received and are expanding our partner opportunities into long term OEM relationships"*

Bluechiip Limited ABN 79 104 795 922

For more information:

Bluechiip Limited

Andrew McLellan

Email: andrew.mclellan@bluechiip.com

Web: www.bluechiip.com

About Bluechiip Limited:

Bluechiip has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).

The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature, can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip® technology does not. Unlike labels, barcodes and RFID, the bluechiip® technology can sense the temperature of each item a tag is attached to, or embedded in.

The bluechiip® technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip® offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip® tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

The bluechiip® technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Further information is available at www.bluechiip.com

END.